The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
M. Solèr(Harvard University), Giovanni Della Cioppa(Asahi Glass (Belgium))
Cited by 826
Related Papers
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma
|Clinical & Experimental Allergy|2004|520